French Study Supports Cetuximab in Esophageal Cancer

Cetuximab (Erbitux) may be an active addition to chemoradiation and chemotherapy for the treatment of locally advanced esophageal cancer, according to the final results of an open-label, single-arm multicenter phase II study conducted in France by the Groupe Cooperateur Multidisciplinaire en Oncologie (GERCOR).¹

http://www.ascopost.com/articles/february-15-2011/french-study-supports-cetuximab-in-esophageal-cancer